Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD raised its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 596.3% during the fourth quarter, HoldingsChannel reports. The firm owned 1,109,978 shares of the company’s stock after purchasing an additional 950,557 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Janux Therapeutics were worth $59,429,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JANX. Russell Investments Group Ltd. lifted its holdings in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares in the last quarter. Avanza Fonder AB purchased a new position in Janux Therapeutics in the 4th quarter valued at $139,000. Meeder Asset Management Inc. purchased a new position in Janux Therapeutics in the 4th quarter valued at $159,000. Tower Research Capital LLC TRC lifted its holdings in Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock valued at $205,000 after purchasing an additional 3,436 shares in the last quarter. Finally, Chicago Capital LLC purchased a new position in Janux Therapeutics in the 4th quarter valued at $230,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

JANX has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Scotiabank reduced their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. Finally, Wedbush reiterated an “outperform” rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $95.25.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. This represents a 3.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The shares were acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 10,002 shares of company stock worth $348,203 over the last three months. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Trading Up 3.8 %

Shares of JANX opened at $32.23 on Tuesday. The firm has a market cap of $1.90 billion, a P/E ratio of -27.55 and a beta of 3.27. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The company’s 50-day moving average price is $29.97 and its 200 day moving average price is $42.96.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.